The impact of ranibizumab on the level of intercellular adhesion molecule type 1 in the vitreous of eyes with proliferative diabetic retinopathy.
OBJECTIVE
This study was to investigate the impact of ranibizumab on the level of intercellular adhesion molecule type 1 (ICAM-1) in the vitreous of eyes with PDR.


METHODS
This is an interventional case-control study. A total of 82 eyes from 82 patients who had undergone vitreous surgery for the treatment of retinal disorders were included. Twenty-two eyes with PDR received an intravitreal ranibizumab injection (IVR) 3-7 days before vitrectomy and were grouped as 'PDR with recent IVR' or Group 1. Sixteen eyes with PDR received IVR more than 7 days before vitrectomy and were grouped as 'PDR with remote IVR' or Group 2. Twenty-two matched PDR eyes did not receive IVR before vitrectomy and were grouped as 'PDR without IVR' or Group 3. Finally, 22 eyes from 22 patients with idiopathic macular pucker (IMP) served as the 'non-diabetic control' group, or Group 4. Vitreous samples were obtained at the time of vitrectomy from all eyes, and the levels of vascular endothelium growth factor (VEGF) and ICAM-1 were analysed using ELISA.


RESULTS
PDR without IVR (Group 3) had the highest vitreous VEGF concentration; the difference was significant compared with those in the PDR with recent IVR (Group 1), PDR with remote IVR (Group 2) and the non-diabetic control group (Group 4) (p < 0.001). Group 2 had a lower vitreous VEGF level than Group 1 (p = 0.041). Group 1 had the highest vitreous ICAM-1 levels (p < 0.001 versus. Groups 2, 3 and 4); Group 2 had a lower vitreous ICAM-1 level than Group 3 (p = 0.028).


CONCLUSIONS
The vitreous fluid level of ICAM-1 was significantly increased within 1 week of IVR administration, but markedly decreased after a week of administration in eyes with PDR. This suggests that leucostasis, vascular leakage and endothelial dysfunction may be amplified in the early days after IVR, but that a therapeutic effect of IVR in these processes may appear after 1 week of ranibizumab administration in eyes with PDR.
Department of Ophthalmology, Wuhan General Hospital of Guangzhou Command, Wuhan, Hubei, China.
Ying
Y
Yan
Department of Ophthalmology, Wuhan General Hospital of Guangzhou Command, Wuhan, Hubei, China.
Li
L
Zhu
Department of Ophthalmology, Wuhan General Hospital of Guangzhou Command, Wuhan, Hubei, China.
Ling
L
Hong
Department of Ophthalmology, Wuhan General Hospital of Guangzhou Command, Wuhan, Hubei, China.
Jun
J
Deng
Department of Ophthalmology, Wuhan General Hospital of Guangzhou Command, Wuhan, Hubei, China.
Yanpin
Y
Song
Department of Ophthalmology, Wuhan General Hospital of Guangzhou Command, Wuhan, Hubei, China.
Xiao
X
Chen
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D016022:Case-Control Studies; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000378:metabolism*; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D000069579:Ranibizumab / Q000627:therapeutic use*; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000378:metabolism; D014821:Vitrectomy; D014822:Vitreous Body / Q000378:metabolism*
D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D018799:Intercellular Adhesion Molecule-1; D000069579:Ranibizumab
intercellular adhesion molecule type 1; proliferative diabetic retinopathy; ranibizumab; vascular endothelium growth factor